Expertise in
41
conditions

Hanns Lochmuller

Central Parkway, 
Newcastle Upon Tyne, ENG, GB 
Expertise in
41
conditions
Central Parkway, 
Newcastle Upon Tyne, ENG, GB 
OverviewLocationsClinical Research

Overview

Hanns Lochmuller practices in Newcastle Upon Tyne, United Kingdom. Mr. Lochmuller is highly rated in 41 conditions, according to our data. His top areas of expertise are Congenital Myasthenic Syndrome, Myotonic Dystrophy, Myotonic Dystrophy Type 2, and Paramyotonia Congenita.

His clinical research consists of co-authoring 418 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Central Parkway, Newcastle Upon Tyne, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Active_not_recruiting
Publish Date: December 16, 2024
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
Enrollment Status: Completed
Publish Date: September 08, 2023
Intervention Type: Drug
Study Drug: Tideglusib
Study Phase: Phase 2/Phase 3
A Multicenter Open-Label Study on the Safety and Efficacy of Deflazacort (Emflaza) in Subjects With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
A Multicenter Open-Label Study on the Safety and Efficacy of Deflazacort (Emflaza) in Subjects With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
Enrollment Status: Terminated
Publish Date: June 27, 2022
Intervention Type: Drug
Study Phase: Phase 3
Myotonic Dystrophy Type 1 (DM1) Deep Phenotyping to Improve Delivery of Personalized Medicine and Assist in the Planning, Design and Recruitment of Clinical Trials
Myotonic Dystrophy Type 1 (DM1) Deep Phenotyping to Improve Delivery of Personalized Medicine and Assist in the Planning, Design and Recruitment of Clinical Trials
Enrollment Status: Completed
Publish Date: April 13, 2021
A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400mg Or 1000mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy
A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400mg Or 1000mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy
Enrollment Status: Completed
Publish Date: December 27, 2018
Intervention Type: Drug
Study Phase: Phase 2
GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)
GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)
Enrollment Status: Completed
Publish Date: April 27, 2018
View 5 Less Clinical Trials

417 Total Publications

Thinking outside the box: A re-evaluation of Canadian recommended outcome measures in adult spinal muscular atrophy - report of a national consensus workshop.
Thinking outside the box: A re-evaluation of Canadian recommended outcome measures in adult spinal muscular atrophy - report of a national consensus workshop.
Journal: Journal of neuromuscular diseases
Published: May 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lochmuller's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 27 Advanced Conditions
View All 71 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile